Related references
Note: Only part of the references are listed.Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2α for degradation by hypoxia- and pVHL-independent regulation
Li Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting
Mark W. Dewhirst
CANCER RESEARCH (2007)
HIF-I and tumour radiosensitivity
B. J. Moeller et al.
BRITISH JOURNAL OF CANCER (2006)
Endogenous markers of two separate, hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial
MI Koukourakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1
LM Brown et al.
MOLECULAR PHARMACOLOGY (2006)
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
BJ Moeller et al.
CANCER CELL (2005)
Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer
K Smith et al.
CANCER RESEARCH (2005)
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1
KJ Williams et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer
MI Koukourakis et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages
KL Talks et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Cancer vascularization: Implications in radiotherapy?
MI Koukourakis et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
